Predict your next investment

Corporation
ENVIRONMENTAL SERVICES & EQUIPMENT | Environmental & Energy Consulting
stok.com

See what CB Insights has to offer

Stage

Loan | Merged

Total Raised

$680K

About stok

stok provides sustainable design, project management, and engineering and commissioning services.On December 2, 2019, stok was acquired by Brummitt Energy. The terms of the agreement were not disclosed.

stok Headquarter Location

945 Front St B

San Francisco, California, 94111,

United States

(415) 329-7100

Latest stok News

Stoke Therapeutics To Present At The Cantor Global Healthcare Virtual Conference

Sep 22, 2021

Stoke Therapeutics To Present At The Cantor Global Healthcare Virtual Conference Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M. Author: Sep 22, 2021 4:30 PM EDT Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET. A live audio webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & Media section of Stoke's website at https://investor.stoketherapeutics.com/ . A replay of the webcast will be available for 30 days following the fireside chat. About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx. View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005948/en/ By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.